Literature DB >> 2138431

Experimental chronic Lyme borreliosis in Lewis rats.

K D Moody1, S W Barthold, G A Terwilliger, D S Beck, G M Hansen, R O Jacoby.   

Abstract

The course of Lyme borreliosis in LEW/N rats inoculated intraperitoneally as infants with 10(6) Borrelia burgdorferi was followed for 360 days. Spirochetes were detected in the blood through 30 days, in the brain through 60 days, and persisted in the spleen, liver, kidneys and articular tissue through 360 days. Acute exudative arthritis, tendonitis, and bursitis were evident in multiple joints by day 30. Arthritis regressed thereafter but capsular fibrosis and lymphoplasmacytic infiltrates persisted throughout the study. Several rats developed exacerbations of acute arthritis within days 180-360, a pattern similar to that encountered in human Lyme disease. Rats had a high prevalence of nonsuppurative myocarditis and vasculitis during days 90-360. Spirochetes were visualized by microscopy in joints and other tissues during the first month of infection, but were seen only sporadically thereafter. All rats seroconverted to B. burgdorferi by day 30. IgM titers persisted and IgG titers rose progressively through day 360. Immunoblots revealed IgM reactivity to a single 41 kDa protein until 360 days, when reactivity to a 60 kDa protein emerged. IgG reactivity occurred against progressively more proteins with time, indicating continued antigenic stimulation. Chronic and recurrent arthritic lesions and myocardial involvement suggest that the rat is a reliable model for further investigation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138431     DOI: 10.4269/ajtmh.1990.42.165

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  32 in total

1.  Lyme borreliosis: host responses to Borrelia burgdorferi.

Authors:  A Szczepanski; J L Benach
Journal:  Microbiol Rev       Date:  1991-03

2.  Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice.

Authors:  S W Barthold; D H Persing; A L Armstrong; R A Peeples
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

3.  Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis.

Authors:  Jameson T Crowley; Klemen Strle; Elise E Drouin; Annalisa Pianta; Sheila L Arvikar; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  J Autoimmun       Date:  2016-02-26       Impact factor: 7.094

Review 4.  Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?

Authors:  Emir Hodzic
Journal:  Bosn J Basic Med Sci       Date:  2015-07-08       Impact factor: 3.363

5.  Intracranial aneurysms in three patients with disseminated Lyme borreliosis: cause or chance association?

Authors:  J Oksi; H Kalimo; R J Marttila; M Marjamäki; P Sonninen; J Nikoskelainen; M K Viljanen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

6.  A guinea pig model for Lyme disease.

Authors:  S W Sonnesyn; J C Manivel; R C Johnson; J L Goodman
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

7.  Passive immunizing activity of sera from mice infected with Borrelia burgdorferi.

Authors:  S W Barthold; L K Bockenstedt
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

8.  Chronic Lyme borreliosis in the laboratory mouse.

Authors:  S W Barthold; M S de Souza; J L Janotka; A L Smith; D H Persing
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  Antigenic stability of Borrelia burgdorferi during chronic infections of immunocompetent mice.

Authors:  S W Barthold
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

Authors:  K D Moody; R L Adams; S W Barthold
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.